Skip to main content
. Author manuscript; available in PMC: 2014 Oct 20.
Published in final edited form as: Hepatology. 2010 Apr;51(4):1168–1175. doi: 10.1002/hep.23477

Table 6. KIR2DL3 and Group 1 HLA-C Associations in Treatment Cohort.

SVR n (%) No SVR n (%) P Value (Pc) OR (95% CI)
Number of patients 107 101
2DL3+Cw*01 6 (5.6) 6 (5.9) 0.92
2DL3+Cw*03 24 (22.4) 8 (7.9) 0.004 (0.03) 3.4 (1.5-8.7)
2DL3+Cw*07 48 (44.9) 45 (44.6) 0.96
2DL3+Cw*08 13 (12.1) 6 (5.9) 0.12
2DL3+Cw*12 13 (12.1) 4 (4.0) 0.03 (>0.1) 3.4 (1.0-14.6)
2DL3+Cw*14 4 (3.7) 2 (2.0) 0.57
2DL3+Cw*16 5 (4.7) 9 (8.9) 0.22